A new approach to killing C. difficile that silences key bacterial genes while sparing other bacteria may provide a new way to treat the most common hospital-acquired bacterial infection in the United States, according to researchers.
While conventional antibiotics treat bacterial infections, they can also cause a condition in the colon called C. difficile infection, due to the drug killing both good and bad bacteria in the gut.
In a lab, researchers created three new antibiotics that kill C. difficile by preventing the expression of bacterial genes that are important for its survival. This approach — called antisense therapy — allows the drug to kill only C. difficile, unlike many antibiotics that kill multiple forms of bacteria.
“We were able to show that these drugs can zero in on and kill C. difficile bacteria while leaving other bacteria alone,” said Arun Sharma, associate professor of pharmacology, Penn State College of Medicine. “We’re still working to refine these drugs and make them even better, with the eventual goal of testing them clinically.”
David Stewart, an associate professor of surgery at the University of Arizona who along with Sharma is a co-principal investigator on this study, said the drug works in a completely different manner than the antibiotics currently used.
“These drugs are organism specific, meaning that they target only one kind of bacteria, kind of like smart antibiotics,” Stewart said. “They’re precise. And that’s especially important with C. difficile infections because this bacteria is uniquely, selectively advantaged to exploit ecological disturbances in the human gut.”
While C. difficile is normally present in the gut, other “good” bacteria are also present, and all these bacteria contribute to a person’s microbiome. When a person’s microbiome is healthy and balanced, it keeps bad bacteria like C. difficile under control.
But if a patient takes an antibiotic for another condition, the antibiotic kills many different types of bacteria, including the good ones keeping C. difficile under control. This allows C. difficile to thrive, causing an infection that can result in severe gastrointestinal symptoms. Since antibiotics can contribute to C. difficile infections, the researchers said a new, alternative treatment for these infections is desirable.
“Ideally, a treatment for C. difficile would have no effect on other bacteria,” Stewart said.
The researchers, who recently published their findings in the Journal of Antibiotics, said that while most antibiotics lack organismal specificity — the ability to target just one type of organism — antisense treatments show great potential for being able to target only specific bacteria.
“Our antisense antibiotics contain genetic material which is complementary to bacterial genetic material, so we designed our genetic material to target specific genes in C. difficile,” Stewart said. “And when our genetic material binds to the bacterial genetic material, it prevents the expression of bacterial genes. And that can cause C. difficile to die.”
The drug tested in the study consisted of two components: the antisense compound that targeted the genetic material in C. difficile — referred to as an antisense oligonucleotide (ASO) — and a carrier compound that transported the ASO into the bacteria, referred to by the research team as a CAB. The researchers tested three versions of the drug, each with a different version of CAB.
The researchers tested each compound to see how much of the drug was required to kill C. difficile bacteria, whether it was toxic or not to human colon cells, and whether it also harmed other bacteria normally found in the gut — like E. coli.
“Ultimately, we wanted these compounds to deliver the drug into the C. difficile bacteria without hurting other bacteria or the patient,” Sharma said. “After testing these three, we found that one carrier in particular — CYDE-21 — was the best at delivering an effective dose of the drug into the bacteria.”
In the future, the researchers said they will conduct further studies to continue to refine the carriers to increase their capacity and minimize their effect on other bacteria and human cells.
“In this study, as a first effort, the carrier is pretty good, and we’d like to do even better,” Stewart said. “It has minimal antibacterial activity, minimal toxicity and it’s an effective carrier of our cargo. So what we’re working on now is modifying our carriers for future testing in preparation for animal studies.”
The Latest on: Antisense therapy
via Google News
The Latest on: Antisense therapy
- FDA clears rare disease therapy from Akcea, Ionis on October 6, 2018 at 10:10 pm
Approval of Tegsedi is a needed win for Akcea and Ionis, which recently saw the FDA reject another drug that uses the same antisense technology as Tegsedi. Ionis is the majority owner of Akcea. The ap... […]
- Raised Lp(a) Slashed in CV Patients on Novel Antisense Agent: Top-Line Results on September 24, 2018 at 12:52 pm
The double-blind study randomly assigned 286 patients with clinical coronary artery disease, stroke, or peripheral vascular disease and Lp(a) levels of at least 60 mg/dL to receive the antisense agent ... […]
- Gene Therapy and Antisense Drugs Market Causes for Increasing Demand 2025 on July 25, 2018 at 5:17 pm
San Francisco, CA -- (SBWIRE) -- 07/25/2018 -- Global Gene Therapy and Antisense Drugs Market: Snapshot Since an escalating number of patients are being diagnosed with cancer every day, the global dem... […]
- Presentations at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases on April 17, 2018 at 9:15 am
Topics will include: In addition to the topics listed above, the conference will feature a special session entitled, 'Neuroscience in the Clinic: Antisense Oligonucleotide (ASO) Therapy', Monday, Apri... […]
- AZ buys Ionis’ NASH candidate on April 10, 2018 at 1:37 am
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million. The move, which builds on an existing strategic par... […]
- New biotech launched for antisense program targeting Angelman syndrome on February 22, 2018 at 6:11 am
Editor’s Note: The Orphan Disease Center receives funding from FAST to develop a gene therapy for treating AS. GTX-101 is an investigational antisense oligonucleotide designed to inhibit transcription ... […]
- Antisense therapy—a promising new way to treat neurological disease on December 13, 2017 at 4:00 pm
A new treatment for Huntington's disease – a deadly brain disorder – has successfully completed first-in-human trials. The drug lowered levels of the harmful huntingtin protein in the spinal fluid of ... […]
- 3 Things In Biotech You Should Learn Today: November 17, 2017 on November 17, 2017 at 5:04 am
Roche gets the first hemophilia A approval in a long time. Ionis licenses antisense therapy for GI autoimmune disease. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a dai... […]
- Gene Therapy and Antisense Drugs Market 2017 Research in-Depth Analysis, Applications, Forecasts to 2025 on February 22, 2017 at 1:36 pm
The research report is a valuable tool for comprehending the progression of the global gene therapy and antisense drugs market between 2017 and 2025. Albany, NY -- (SBWIRE) -- 02/22/2017 -- Global Gen... […]
via Bing News